MTX-463-I201 Mediar Study -A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Mediar Therapeutics, Inc.
Start Date
October 27, 2025
End Date
July 4, 2030
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Mediar Therapeutics, Inc.
Start Date
October 27, 2025
End Date
July 4, 2030